Abstract p53 is a powerful tumor suppressor and is an attractive cancer therapeutic target. A
breakthrough in cancer research came from the discovery of the drugs which are capable of …

Background In a multinational, phase 3, head-to-head trial, ibrutinib, a Bruton's tyrosine
kinase (BTK) inhibitor, was compared with zanubrutinib, a BTK inhibitor with greater …

Treatment standards for chronic lymphocytic leukemia (CLL) have been transformed with the
advent of effective inhibitors of B-cell receptor signaling such as ibrutinib–a first-in-class …

Background The combination melphalan–prednisone–thalidomide (MPT) is considered a
standard therapy for patients with myeloma who are ineligible for stem-cell transplantation …

Background Panobinostat is a potent oral pan-deacetylase inhibitor that in preclinical
studies has synergistic anti-myeloma activity when combined with bortezomib and …

Abstract Consensus Panel 4 (CP4) of the 11th International Workshop on Waldenstrom's
Macroglobulinemia (IWWM-11) was tasked with reviewing the current criteria for diagnosis …

Here we show that overexpression or activation of B-cell maturation antigen (BCMA) by its
ligand, a proliferation-inducing ligand (APRIL), promotes human multiple myeloma (MM) …

This FIRST trial final analysis examined survival outcomes in patients with transplant-
ineligible newly diagnosed multiple myeloma (NDMM) treated with lenalidomide and low …

Purpose: We study CD38 levels in immunosuppressive CD4+ CD25highFoxp3+ regulatory
T cells (Treg) and further define immunomodulating effects of a therapeutic CD38 mAb …

Summary Background Sintilimab (Innovent Biologics, Suzhou, China), a highly selective,
fully humanised, monoclonal antibody, blocks the interaction between PD-1 and its ligands …